Skip to content

Study · In vitro (cells) · pseudomonas aeruginosa · 2026

7 results

Murepavadin is a novel peptide antibiotic that exhibits potent antibiofilm activity and enhances the efficacy of conventional antibiotics against Pseudomonas aeruginosa.

Yılmaz U, Erkoç Güleryüz Ö, Ünlü M, Vardar Ünlü G

Biofouling16 Jul 2026

PMID42459059 (opens in a new tab)DOI10.1080/08927014.2026.2698818 (opens in a new tab)PepBankPUB-42459059
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In clinical isolates, murepavadin had a planktonic MIC50 of 0.25 mg/l.

    In plain wordsIn lab tests, murepavadin had a planktonic MIC50 of 0.25 mg/l.

    Peptide
    Murepavadin
    Outcome
    Not applicablePlanktonic MIC50
    Study

    Pseudomonas aeruginosan = 50

    Clinical isolates
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Measurements

    MIC50
    0.25 mg/l
    planktonic cells

    Source sentences

    Summary
    MUR showed potent activity against planktonic cells (MIC50/90: 0.25/0.5 mg l-1).
    2 context sentences
    Summary · context
    The minimum inhibitory concentrations (MICs) of 50 isolates against MUR and five antibiotics were determined.
    Summary · context
    This study evaluates the antimicrobial and antibiofilm efficacy of murepavadin (MUR), a novel peptidomimetic targeting the LptD protein, alone and combined with conventional antibiotics against clinical isolates.
  2. 02LabIn vitro (cells)Activity measurement

    In clinical isolates, murepavadin had a planktonic MIC90 of 0.5 mg/l.

    In plain wordsIn lab tests, murepavadin had a planktonic MIC90 of 0.5 mg/l.

    Peptide
    Murepavadin
    Outcome
    Not applicablePlanktonic MIC90
    Study

    Pseudomonas aeruginosan = 50

    Clinical isolates
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Measurements

    MIC90
    0.5 mg/l
    planktonic cells

    Source sentences

    Summary
    MUR showed potent activity against planktonic cells (MIC50/90: 0.25/0.5 mg l-1).
    2 context sentences
    Summary · context
    The minimum inhibitory concentrations (MICs) of 50 isolates against MUR and five antibiotics were determined.
    Summary · context
    This study evaluates the antimicrobial and antibiofilm efficacy of murepavadin (MUR), a novel peptidomimetic targeting the LptD protein, alone and combined with conventional antibiotics against clinical isolates.
  3. 03LabIn vitro (cells)Activity measurement

    In biofilms, murepavadin demonstrated significantly lower minimum biofilm inhibitory concentrations, with no comparator specified.

    In plain wordsIn lab tests, murepavadin had significantly lower concentrations needed to inhibit biofilm, with no comparator specified.

    Peptide
    Murepavadin
    Outcome
    DecreaseMinimum biofilm inhibitory concentration
    Study

    Pseudomonas aeruginosan: not reported in source

    Clinical isolates
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In biofilms, MUR demonstrated significantly lower MBIC and lower concentrations required for ≥90% biomass reduction (CV staining).
    1 context sentence
    Summary · context
    This study evaluates the antimicrobial and antibiofilm efficacy of murepavadin (MUR), a novel peptidomimetic targeting the LptD protein, alone and combined with conventional antibiotics against clinical isolates.
  4. 04LabIn vitro (cells)Activity measurement

    In biofilms, murepavadin required lower concentrations for ≥90% biomass reduction, with no comparator specified.

    In plain wordsIn lab tests, murepavadin required lower concentrations for ≥90% biofilm biomass reduction, with no comparator specified.

    Peptide
    Murepavadin
    Outcome
    DecreaseConcentration for biomass reduction
    Study

    Pseudomonas aeruginosan: not reported in source

    Clinical isolates
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In biofilms, MUR demonstrated significantly lower MBIC and lower concentrations required for ≥90% biomass reduction (CV staining).
    1 context sentence
    Summary · context
    This study evaluates the antimicrobial and antibiofilm efficacy of murepavadin (MUR), a novel peptidomimetic targeting the LptD protein, alone and combined with conventional antibiotics against clinical isolates.

Studies that did not test the peptide alone3

In this study, Murepavadin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Murepavadin.

  1. 05LabNot a test of Murepavadin aloneIn vitro (cells)Activity measurement

    In vitro, murepavadin and colistin showed consistent synergy across all strains.

    In plain wordsIn lab tests, murepavadin and colistin showed synergy across all strains.

    Peptide
    Murepavadin
    Outcome
    IncreaseColistin synergy
    Study

    Pseudomonas aeruginosan: not reported in source

    Clinical isolates
    Outcome group
    Infection and antimicrobial activity · Infection

    Source sentences

    Summary
    Synergy tests revealed consistent MUR-colistin synergy across all strains, with notable interactions against carbapenemase-producers when combined with meropenem.
    1 context sentence
    Summary · context
    This study evaluates the antimicrobial and antibiofilm efficacy of murepavadin (MUR), a novel peptidomimetic targeting the LptD protein, alone and combined with conventional antibiotics against clinical isolates.

    In this study, Murepavadin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Murepavadin.

  2. 06LabNot a test of Murepavadin aloneIn vitro (cells)Activity measurement

    In vitro, murepavadin combined with meropenem showed notable interactions against carbapenemase-producing isolates.

    In plain wordsIn lab tests, murepavadin with meropenem showed notable interactions against carbapenemase-producing bacteria.

    Peptide
    Murepavadin
    Outcome
    Direction not reportedMeropenem interaction
    Study

    Pseudomonas aeruginosan: not reported in source

    Clinical isolates
    Outcome group
    Infection and antimicrobial activity · Infection

    Source sentences

    Summary
    Synergy tests revealed consistent MUR-colistin synergy across all strains, with notable interactions against carbapenemase-producers when combined with meropenem.
    1 context sentence
    Summary · context
    This study evaluates the antimicrobial and antibiofilm efficacy of murepavadin (MUR), a novel peptidomimetic targeting the LptD protein, alone and combined with conventional antibiotics against clinical isolates.

    In this study, Murepavadin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Murepavadin.

  3. 07LabNot a test of Murepavadin aloneIn vitro (cells)Activity measurement

    In vitro, murepavadin-antibiotic combinations showed synergistic biofilm inhibition, most pronounced with tobramycin.

    In plain wordsIn lab tests, murepavadin-antibiotic combinations showed synergistic biofilm inhibition, strongest with tobramycin.

    Peptide
    Murepavadin
    Outcome
    IncreaseSynergistic biofilm inhibition
    Study

    Pseudomonas aeruginosan: not reported in source

    Clinical isolates
    Outcome group
    Infection and antimicrobial activity · Infection

    Source sentences

    Summary
    Bliss analysis confirmed strong synergistic biofilm inhibition in all combinations, most pronounced with tobramycin.
    1 context sentence
    Summary · context
    This study evaluates the antimicrobial and antibiofilm efficacy of murepavadin (MUR), a novel peptidomimetic targeting the LptD protein, alone and combined with conventional antibiotics against clinical isolates.

    In this study, Murepavadin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Murepavadin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.